Small molecule · Inhibitor of viral RNA-dependent RNA polymerase (RdRp) · developed by BioCryst Pharmaceuticals
Galidesivir is an adenosine analog that is metabolized intracellularly to its active triphosphate form. The triphosphate is incorporated into the growing viral RNA strand by the viral RNA-dependent RNA polymerase, causing premature chain termination and blocking viral transcription and replication. It is studied in filovirus infections, including Ebola virus infection and Marburg virus disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03800173 | Phase 1 | Marburg Virus Disease | Completed | BCRX |
| NCT02319772 | Phase 1 | Filovirus Infections | Completed | BCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ebola Virus InfectionFilovirus InfectionsMarburg Virus Disease
See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BCRX catalysts and pipeline →